Healio

BE SURE study: Bimekizumab achieves PASI 90 at 16 weeks in psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The investigational IL-17A and IL-17F inhibitor ...
Pharmabiz

UCB announces positive results from phase 3 BE SURE study of bimekizumab as compared to adalimumab in adults with moderate-to-severe plaque psoriasis

UCB, a global biopharmaceutical company, announced the detailed results of the head-to-head phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F ...
Monthly Prescribing Reference

Bimekizumab Beats Adalimumab in Plaque Psoriasis Trial

Chronic plaque psoriasis is a condition in which epithelial cells are over produced and form a well-defined site. The redness is often covered with silvery scales of skin. The cause of this type of ...
Nasdaq

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

BRUSSELS, Dec. 6, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE ...
Healio

Bimekizumab for psoriasis demonstrates safety, efficacy in phase 3 studies

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at AAD VMX 2021 presented the results of the ...